Ultragenyx Pharmaceutical Inc.
General ticker "RARE" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $2.9B (TTM average)
Ultragenyx Pharmaceutical Inc. follows the US Stock Market performance with the rate: 6.4%.
Estimated limits based on current volatility of 2.1%: low 25.31$, high 26.38$
Factors to consider:
- Total employees count: 1371 (+6.0%) as of 2025
- North America accounted for 60.8% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Operating losses, Capital raising, Clinical development risks, Regulatory and compliance, Manufacturing risks
- Price in estimated range
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [17.48$, 42.18$]
- 2026-12-31 to 2027-12-31 estimated range: [15.40$, 37.64$]
Financial Metrics affecting the RARE estimates:
- Negative: with PPE of -5.0 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -16.29 <= 0.28
- Positive: Investing cash flow per share per price, % of 8.25 > -0.64
- Positive: Shareholder equity ratio, % of -5.22 <= 18.97
- Negative: negative Industry operating income (median)
- Positive: Inventory ratio change, % of -0.26 <= 0
- Negative: negative Net income
- Positive: Interest expense per share per price, % of 2.17 <= 3.34
Short-term RARE quotes
Long-term RARE plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $434.25MM | $560.23MM | $673.00MM |
| Operating Expenses | $1,003.46MM | $1,096.20MM | $1,208.00MM |
| Operating Income | $-569.21MM | $-535.97MM | $-535.00MM |
| Non-Operating Income | $-39.26MM | $-31.61MM | $-36.00MM |
| Interest Expense | $66.00MM | $63.04MM | $62.00MM |
| R&D Expense | $648.45MM | $697.87MM | $750.00MM |
| Income(Loss) | $-608.46MM | $-567.59MM | $-571.00MM |
| Taxes | $-1.82MM | $1.60MM | $4.00MM |
| Net Income(Loss)* | $-606.64MM | $-569.18MM | $-575.00MM |
| Stockholders Equity | $275.41MM | $255.00MM | $-80.00MM |
| Inventory | $33.97MM | $45.01MM | $52.00MM |
| Assets | $1,491.01MM | $1,503.00MM | $1,532.00MM |
| Operating Cash Flow | $-475.00MM | $-414.19MM | $-466.00MM |
| Capital expenditure | $46.77MM | $7.49MM | $6.00MM |
| Investing Cash Flow | $168.00MM | $-17.77MM | $236.00MM |
| Financing Cash Flow | $388.00MM | $399.24MM | $478.00MM |
| Earnings Per Share** | $-8.25 | $-6.29 | $-5.83 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.